Table 3. Cell-cycle modulation and apoptotic index.

Cells	Treatment	G0/G1 phase (%)	S phase (%)	G2/M phase (%)	Apoptotic index (%)
NCI-H2052	Control	69.9±4.2	12.8±1.4	17.3±2.0	1.3±0.2
	Carboplatin	64.2±7.1	13.6±0.9	22.2±1.4	5.0±0.4
	Pemetrexed	70.3±6.3	24.5±2.5	5.2±0.2	4.5±0.7
	Vandetanib	78.2±8.5	9.3±0.8	12.5±0.2	6.4±0.2
	Pemetrexed+carboplatin	63.2±6.9	15.8±3.7	21.0±2.5	11.3±1.9*
	Pemetrexed+vandetanib	65.7±4.8	17.9±3.2	16.4±1.6	12.6±2.5*
	Carboplatin+vandetanib	60.4±5.6	16.8±0.3	22.8±0.9	13.1±3.3*
	Pemetrexed+carboplatin+vandetanib	58.8±4.1	19.2±1.1	22.0±3.0	19.4±2.8**
NCI-H2452	Control	75.3±7.8	17.3±4.1	7.4±0.5	1.1±0.3
	Carboplatin	72.9±5.3	14.8±1.2	12.3±1.7	4.1±1.2
	Pemetrexed	69.5±6.4	24.0±2.2	6.5±0.4	3.5±0.4
	Vandetanib	80.4±7.2	10.9±1.1	8.7±0.9	3.3±0.5
	Pemetrexed+carboplatin	52.6±4.9	32.8±4.1	14.6±1.1	9.5±2.6*
	Pemetrexed+vandetanib	47.0±4.4	37.2±4.0	15.8±1.2	10.7±1.9*
	Carboplatin+vandetanib	54.9±5.7	29.6±2.1	15.5±1.0	11.4±2.3*
	Pemetrexed+carboplatin+vandetanib	47.2±3.8	37.6±3.1	15.2±0.9	20.5±4.1**
NCI-H28	Control	69.9±7.1	12.8±0.3	17.3±1.7	1.3±0.2
	Carboplatin	60.3±5.1	14.5±1.1	25.2±2.2	3.0±1.1
	Pemetrexed	66.2±8.9	16.7±1.1	17.1±1.5	4.5±1.0
	Vandetanib	74.2±4.1	7.5±0.9	18.3±1.6	7.7±1.3
	Pemetrexed+carboplatin	50.0±4.6	28.6±3.1	21.4±2.3	11.2±1.2*
	Pemetrexed+vandetanib	42.8±3.5	19.0±2.0	38.2±3.1	13.5±3.3*
	Carboplatin+vandetanib	46.1±4.8	14.7±1.3	39.2±2.6	11.1±2.8*
	Pemetrexed+carboplatin+vandetanib	51.1±5.7	26.9±3.2	22.0±4.0	18.2±1.8**
MSTO-211H	Control	57.5±6.1	19.2±1.1	23.3±3.0	1.5±0.2
	Carboplatin	50.2±5.1	21.8±2.2	28.0±2.9	4.4±0.3
	Pemetrexed	56.1±5.5	31.4±3.0	12.5±1.1	10.1±2.2
	Vandetanib	71.0±6.8	10.7±1.3	18.3±2.1	4.2±0.7
	Pemetrexed+carboplatin	40.3±4.0	34.5±3.1	25.2±2.6	15.1±2.5*
	Pemetrexed+vandetanib	28.7±2.6	32.9±4.1	38.4±3.1	17.3±3.1*
	Carboplatin+vandetanib	30.3±2.9	28.7±1.3	41.0±0.9	15.9±2.7*
	Pemetrexed+carboplatin+vandetanib	27.5±3.1	36.1±4.5	36.4±2.7	26.4±3.3**

^*P<0.05 with respect to control cells, ^**P<0.05 with respect to pemetrexed+carboplatin-treated cells.